Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1374250 | 0.84 | ALDH1A1 (0.47) | ALDH1A1LMNACA12CA1CA2 | |
| SCHEMBL30727315 | 0.83 | LMNA (0.49) | PSIP1ALDH1A1LMNAKDM4ENPSR1 | |
| SCHEMBL31248447 | 0.83 | CA12 (0.44) | ALDH1A1KDM4ECA12CA1CA2 | |
| SCHEMBL30811026 | 0.83 | CA12 (0.44) | ALDH1A1LMNAKDM4ECA12CA1 | |
| SCHEMBL23732506 | 0.83 | GAA (0.55) | PSIP1ALDH1A1LMNACA12CA1 | |
| SCHEMBL23919240 | 0.83 | KMT2A (0.51) | LMNACA12CA1CA2CA4 | |
| SCHEMBL7886274 | 0.83 | PSIP1 (0.50) | PSIP1ALDH1A1LMNAKDM4ENPSR1 | |
| SCHEMBL8942619 | 0.83 | PSIP1 (0.50) | PSIP1ALDH1A1LMNAKDM4ENPSR1 | |
| SCHEMBL30811038 | 0.83 | PLCG1 (0.48) | LMNANPSR1CA12CA1CA2 | |
| SCHEMBL7371896 | 0.82 | GAA (0.56) | ALDH1A1LMNAKDM4ECA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115029833-A | Flame-retardant fancy yarn and preparation process thereof | 江阴市聚鑫花式线有限公司 | 2022-09-09 | — | — | CN | claimed |
| CN-115012086-A | Fancy yarn dyed by vegetable dye and processing technology thereof | 江阴市聚鑫花式线有限公司 | 2022-09-06 | — | — | CN | claimed |
| EP-0839155-A1 | CYSTEINE PROTEASE INHIBITORS FOR USE IN TREATMENT OF IgE MEDIATED ALLERGIC DISEASES | PEPTIDE THERAPEUTICS LIMITED (GB) | 1998-05-06 | — | — | EP | claimed |
| WO-1997004004-A1 | CYSTEINE PROTEASE INHIBITORS FOR USE IN TREATMENT OF IgE MEDIATED ALLERGIC DISEASES | PEPTIDE THERAPEUTICS LIMITED (GB) | 1997-02-06 | — | — | WO | claimed |
| US-12491252-B2 | Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (EZH2) and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of EZH2 | NORTHWESTERN UNIVERSITY (US) | 2025-12-09 | — | — | US | disclosed |
| CN-114805322-B | Prins reaction and intermediate for synthesizing halichondrin macrolides and analogues thereof | 卫材R&D管理有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-20240335546-A1 | SUBSTITUTED 3-AMINO-5-PHENYLBENZAMIDE COMPOUNDS AS COVALENT INHIBITORS OF ENHANCER ZESTE HOMOLOG 2 (EZH2) AND PROTEOLYSIS-TARGETING CHIMERIC DERIVATIVES THEREOF (PROTACS) THAT INDUCE DEGRADATION OF EZH2 | NORTHWESTERN UNIVERSITY | 2024-10-10 | — | — | US | disclosed |
| US-20240262832-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2024-08-08 | — | — | US | disclosed |
| US-12042543-B2 | Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (EZH2) and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of EZH2 | NORTHWESTERN UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240180158-A1 | COMPOUNDS HAVING SELECTIVE INACTIVATION ACTIVITY | UNIVERSITY OF NORTH CAROLINA AT WILMINGTON (US) | 2024-06-06 | — | — | US | disclosed |
| EP-4329881-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | Vanqua Bio, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20230346953-A1 | SUBSTITUTED 3-AMINO-5-PHENYLBENZAMIDE COMPOUNDS AS COVALENT INHIBITORS OF ENHANCER ZESTE HOMOLOG 2 (EZH2) AND PROTEOLYSIS-TARGETING CHIMERIC DERIVATIVES THEREOF (PROTACS) THAT INDUCE DEGRADATION OF EZH2 | UNITED STATES GOVERNMENT | 2023-11-02 | — | — | US | disclosed |
| WO-1996030353-A1 | REVERSIBLE PROTEASE INHIBITORS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1996-10-03 | — | — | WO | disclosed |
| US-5519048-A | 3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof | MERRELL PHARMACEUTICALS INC. (US) | 1996-05-21 | — | — | US | disclosed |
| EP-0701551-A1 | 3-(INDOL-3-YL) PROPENOIC ACID DERIVATIVES AND AS NMDA ANTAGONISTS | MERRELL PHARMA INC (US) | 1996-03-20 | — | — | EP | disclosed |
| WO-1995023222-A1 | IRREVERSIBLE CYSTEINE PROTEASE INHIBITORS CONTAINING VINYL GROUPS CONJUGATED TO ELECTRON WITHDRAWING GROUPS | KHEPRI PHARMACEUTICALS, INC. (US) | 1995-08-31 | — | — | WO | disclosed |
| WO-1994027964-A1 | 3-(INDOL-3-YL) PROPENOIC ACID DERIVATIVES AND AS NMDA ANTAGONISTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-12-08 | — | — | WO | disclosed |
| EP-0063489-B1 | 4\"-MODIFIED METHYLENE OLEANDOMYCINS | PFIZER INC. (US) | 1984-06-27 | — | — | EP | disclosed |
| EP-0063489-A1 | 4\"-Modified methylene oleandomycins | PFIZER INC. (US) | 1982-10-27 | — | — | EP | disclosed |
| US-4336368-A | 4 Deoxy-4-methylene oleandomycin and derivatives thereof | PFIZER INC. (US) | 1982-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180158-A1 | COMPOUNDS HAVING SELECTIVE INACTIVATION ACTIVITY | GAA, MGAM, GBA3 | PSIP1 4068/4885ALDH1A1 171/4885LMNA 3292/4885 |
| US-12042543-B2 | Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (EZH2) and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of EZH2 | EZH2, BAZ2A, BAZ2B | PSIP1 1270/4885ALDH1A1 2801/4885LMNA 2665/4885 |
| US-20240262832-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | GBA1, GAA, GBA2 | PSIP1 3786/4885ALDH1A1 1938/4885LMNA 2954/4885 |
| US-20230346953-A1 | SUBSTITUTED 3-AMINO-5-PHENYLBENZAMIDE COMPOUNDS AS COVALENT INHIBITORS OF ENHANCER ZESTE HOMOLOG 2 (EZH2) AND PROTEOLYSIS-TARGETING CHIMERIC DERIVATIVES THEREOF (PROTACS) THAT INDUCE DEGRADATION OF EZH2 | EZH2, BAZ2A, BAZ2B | PSIP1 1270/4885ALDH1A1 2801/4885LMNA 2665/4885 |
| US-12491252-B2 | Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (EZH2) and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of EZH2 | EZH2, BAZ2A, BAZ2B | PSIP1 1270/4885ALDH1A1 2801/4885LMNA 2665/4885 |
| US-20240335546-A1 | SUBSTITUTED 3-AMINO-5-PHENYLBENZAMIDE COMPOUNDS AS COVALENT INHIBITORS OF ENHANCER ZESTE HOMOLOG 2 (EZH2) AND PROTEOLYSIS-TARGETING CHIMERIC DERIVATIVES THEREOF (PROTACS) THAT INDUCE DEGRADATION OF EZH2 | EZH2, BAZ2A, BAZ2B | PSIP1 1270/4885ALDH1A1 2801/4885LMNA 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.